Ligand Closes XOMA: A Transformative Pivot Into a Diversified Royalty Compounder
The biotech royalty shop completes its largest-ever acquisition, pairs a 0% convertible with a buyback, and steps into the most catalyst-rich 18 months of its history.
LGND · Earnings Call · 2026-08-06
The Quiet Multiplication of a Royalty Shop
On the surface, Q2 was another steady beat: royalty revenue up 32% to $48 million, total revenue up 34% to $64 million, and adjusted diluted EPS up 48% to $2.37. But the quarter's real news was structural and arrived days after the books closed. Ligand completed the XOMA acquisition — the largest transaction in company history — adding more than 120 commercial, clinical and preclinical assets, including Roche's Vabysmo, Servier/Ipsen's Ojemda and Zevra's Miplyffa. CEO Todd Davis made the strategic case bluntly:
In reality, it does not concentrate our risk due to the broad XOMA portfolio, it further diversifies our risk and accelerates our growth. This means higher growth at lower risk. It also extends the duration of our cash flows, in some cases, through 2040.
The economics are immediately accretive: management guided to roughly $0.50 of adjusted EPS in the second half of 2026 and $1.50 in 2027, with integration expected to capture "virtually all" of XOMA's ~$30 million annual operating expense base (reduced to under $5 million under Ligand's lean model). The transaction nearly doubles the late-stage pipeline and carries ~$2.3 billion of publicly disclosed potential milestones. This is the strategy Davis has described since 2022 — royalty stream aggregation via disciplined underwriting — now scaled up dramatically. As he reminded shareholders, royalty revenue has grown from $73 million in 2022 to a 2026 guide of $225–$250 million, while adjusted EPS climbs from $2.44 to $9–$9.50.
The Balance Sheet Becomes a Weapon
Equally notable was the financing that funded the deal. Ligand sold a $700 million 0-coupon convertible, paired it with a call spread that protects shareholders from dilution up to roughly $524 per share, and repurchased ~229,000 shares for ~$60 million. CFO Octavio Espinoza was explicit about the resulting firepower:
After successfully completing our convertible note offering and closing the XOMA acquisition shortly after quarter end, we still have approximately $700 million of deployable capital. At the same time, we're generating strong operating cash flow in excess of $200 million in 2026, growing to an expected $300 million in 2027.
The leverage is visible in the fundamentals: liabilities-to-assets jumped from ~13% to ~35% as the convertible landed. Liabilities to Assets rose from ~13% to ~35% year over year, a signal that the company is consciously trading an ultra-clean sheet for cheap dry powder. Against that, the economics run deep: Free Cash Flow (less SBC) hit $38M in the quarter, up 213% year over year, on top of a +48% EPS print. The capital stack — royalty cash flows + 0% debt + buyback — is the rare case where financial engineering and the core business model reinforce each other.
Catalyst-Rich and Tax-Efficient
Post-XOMA, Ligand steps into its "most catalyst-rich period" — up to 7 pivotal study readouts over the next 18 months, spanning Orchestra BioMed's AVIM therapy, Ojemda's Phase III frontline pLGG readout (mid-2027), Takeda's Mezagitamab, Rezolute's Ersodetug (H2 2026), volixibat in PBC (Q1 2027) and lasofoxifene. There are also potential FDA approvals — Palvella's Rapamycin rolling NDA should complete by end-2026 with 2027 approval possible — plus geographic launches (Filspari in Japan, Ohtuvayre in China, Ojemda in Japan). Lauren Hay, VP of Portfolio Strategy: “Over the next 18 months, we have as many as 7 pivotal trial readouts alongside potential FDA approvals and geographic expansion opportunities for products already on the market.” — Lauren Hay, Vice President of Portfolio Strategy and Investments · 2026-08-06
The diversification is the point: pivotal study outcomes are acknowledged as binary, but the model is built to absorb misses. A quieter but material value-add is tax: the deal brings more than $110 million of Section 174 R&D tax credits and NOLs, which Octavio expects to “utilize over the next 3 to 5 years” — Octavio Espinoza, Chief Financial Officer · 2026-08-06, enabling meaningful U.S. cash tax savings and underpinning that ~$300 million 2027 cash-flow target.
There's also a subtle accounting shift worth watching — the growing presence of financial royalty assets in the acquired portfolio, where milestone cash may reduce carrying value rather than flow straight to revenue. Management promised additional transparency as these become a larger contributor, reflecting the economics in adjusted measures through amortization. In parallel, the royalty asset base itself was transformed: peak sales potential like Vabysmo's (~$7 billion consensus; roughly $35 million at peak royalty to Ligand) now sets a higher bar for the whole franchise.
The Market Read: Riding the Earnings-Growth Wave
Look at the global tape and LGND sits squarely inside this quarter's top editor-curated theme — Earnings growth. With adjusted EPS up 48% year-over-year and guidance raised (low end to $9.00), the company is one of the cleanest royalty-aggregation stories in the complex. The stock has gained ~40% over the past 90 days and trades ~11% below its July 9 peak — a consolidation after a landmark event rather than a breakdown. Prior calls telegraphed exactly this arc: deal lead Michael Vigilante noted the XOMA transaction “provides XOMA shareholders with liquidity and attractive returns since their pivot to a royalty aggregator model in 2017” — Michael Vigilante, Deal Lead · 2026-05-09, and in May, Davis already framed the strategy's resilience: “We don't need to do additional deals to sustain over 20% growth for the next 5 years.” — Todd Davis, Chief Executive Officer · 2026-05-09 The sub-$100 million deal market (typical $25–$75 million tickets) remains "target rich," per Davis — with royalty capital representing well under 5% of development-stage financing, competition is sparse and underwriting discipline unchanged: “Our strategy and our underwriting criteria as well as target returns remain unchanged. Lower cost of capital just allows us to deliver greater alpha and a spread for our investors.” — Todd Davis, Chief Executive Officer · 2026-08-06 With ~$700 million of deployable capital, a 0% coupon, and a December Investor Day that will unveil a refreshed 5-year outlook, Ligand is positioning itself as the preferred partner of choice in a niche where demand for its proprietary opportunity set keeps compounding.